BTKi Archive - MS-Docblog

BTKi – the direction is right.

19. November 2025 Prof. Dr. med. Mathias Mäurer General

On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1

Anreißerbild für Videointerview zu Entwicklung der MS-Therapie mit dem Porträt von Prof. Mathias Mäurer und dem Videotitel.

Development of MS Therapies

27. September 2025 Prof. Dr. med. Mathias Mäurer MS Therapy

There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.

New Findings on BTKi – the Tolebrutinib Study Program

28. January 2025 Prof. Dr. med. Mathias Mäurer General

At this year’s ECTRIMS Meeting in Copenhagen, the data from the study program of the Bruton-Tyrosine-Kinase (BTK) inhibitor Tolebrutinib was presented. And what can I say – fortunately there were positive news this time.

Merry Christmas and a Happy New Year

18. December 2023 Prof. Dr. med. Mathias Mäurer General, Therapy for MS

The year 2023 is slowly coming to an end. Therefore, as usual at this point, I would like to wish my readers a blessed Christmas season, as well as luck and health for the coming

ECTRIMS 2023 in Milan – “We are halfway home, but we are not all the way there”

26. October 2023 Prof. Dr. med. Mathias Mäurer General, MS Therapy

This year’s annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place from October 12 to 14 in Milan. This most important scientific MS congress discusses the most important

MS-Docblog – Details on the New Class of Active Substances of BTKi

9. October 2022 Prof. Dr. med. Mathias Mäurer General

Bruton tyrosine kinase inhibitors, or BTKi for short, are by no means new. They are known from cancer therapy and have been adapted for the treatment of neurologically degenerative diseases. So, will there soon be

Spritzen sind eine mögliche Darreichungsform in der Behandlung der MS, neben Infusionen und Tabletten.

ECTRIMS 2021 (3): New Therapeutic Concepts

11. November 2021 Prof. Dr. med. Mathias Mäurer General

One of the most exciting topics of large international congresses is the outlook for new therapies that may be able to bring added value in the future. As an immunological treatment strategy, we will probably

Tag: BTKi

BTKi – the direction is right.

Development of MS Therapies

New Findings on BTKi – the Tolebrutinib Study Program

Merry Christmas and a Happy New Year

ECTRIMS 2023 in Milan – “We are halfway home, but we are not all the way there”

MS-Docblog – Details on the New Class of Active Substances of BTKi

ECTRIMS 2021 (3): New Therapeutic Concepts

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community